Health Care [ 4/12 ] | Life Sciences Tools & Services [ 67/74 ]
NYSE | Common Stock
QiagenN. V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally.
The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories.
It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, such as assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing.
The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables, such as short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions.
It offers NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments; bioinformatics solutions; and custom laboratory and genomic services.
The company provides software-as-a-service.
It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers.
The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 6, 25 | 0.61 Increased by +10.91% | 0.62 Decreased by -1.29% |
| Nov 6, 24 | 0.57 Increased by +14.00% | 0.54 Increased by +5.56% |
| Jul 31, 24 | 0.55 Increased by +7.84% | 0.51 Increased by +7.84% |
| Apr 29, 24 | 0.46 Decreased by -9.80% | 0.44 Increased by +4.55% |
| Feb 6, 24 | 0.55 Increased by +3.77% | 0.55 |
| Oct 30, 23 | 0.50 Decreased by -5.66% | 0.48 Increased by +4.17% |
| Aug 8, 23 | 0.51 Increased by 0.00% | 0.50 Increased by +2.00% |
| May 3, 23 | 0.51 Decreased by -36.25% | 0.47 Increased by +8.51% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 521.20 M Increased by +2.36% | 88.32 M Decreased by -9.57% | Increased by +16.95% Decreased by -11.65% |
| Sep 30, 24 | 501.87 M Increased by +5.46% | 98.06 M Increased by +26.01% | Increased by +19.54% Increased by +19.49% |
| Jun 30, 24 | 496.35 M Increased by +0.30% | -183.46 M Decreased by -327.09% | Decreased by -36.96% Decreased by -326.41% |
| Mar 31, 24 | 458.80 M Decreased by -5.48% | 80.67 M Decreased by -5.13% | Increased by +17.58% Increased by +0.37% |
| Dec 31, 23 | 509.16 M Increased by +2.24% | 97.66 M Increased by +9.93% | Increased by +19.18% Increased by +7.51% |
| Sep 30, 23 | 475.89 M Decreased by -4.75% | 77.82 M Decreased by -5.55% | Increased by +16.35% Decreased by -0.84% |
| Jun 30, 23 | 494.86 M Decreased by -4.01% | 80.79 M Decreased by -16.42% | Increased by +16.33% Decreased by -12.93% |
| Mar 31, 23 | 485.40 M Decreased by -22.76% | 85.03 M Decreased by -45.25% | Increased by +17.52% Decreased by -29.12% |